ANI Pharmaceuticals announces FDA approval of purified Cortrophin Gel

Gel has multiple indications including Multiple Sclerosis, Rheumatoid Arthritis and Nephrotic Syndrome

ANI Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental New Drug Application (sNDA) for Purified Cortrophin Gel (Repository Corticotropin Injection USP) (Cortrophin Gel) for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis (MS) and rheumatoid arthritis (RA), in addition to excess urinary protein due to nephrotic syndrome. Cortrophin Gel is an adrenocorticotropic hormone (ACTH), also known as purified corticotropin.

“FDA’s approval of Cortrophin Gel enables us to bring a much-needed treatment choice to patients with acute exacerbations of multiple sclerosis and rheumatoid arthritis as well as nephrotic syndrome, who are coping with a devastating disease on a daily basis,” said Nikhil Lalwani, President and Chief Executive Officer of ANI Pharmaceuticals. “We are pleased to offer Cortrophin Gel, an established treatment, to provide another option to patients and prescribers. This approval reflects ANI’s commitment to the patients and physicians we serve, combined with U.S.-based development and manufacturing. We anticipate a full-scale commercial launch by early in the first quarter of 2022.”

“Patients who are refractory or intolerant to corticosteroids have an especially urgent need for effective alternatives and are at risk of ongoing organ damage with long-term disease,” said Mary Pao Seideman, MD, PhD, Chief Medical Officer of ANI Pharmaceuticals. “For over 30 years, there has only been one available treatment in the ACTH category. With the FDA approval of Cortrophin Gel, patients will now have a significant new treatment option.”

Cortrophin Gel was first approved in 1954 and used for decades to treat certain chronic autoimmune disorders. ANI acquired the NDA for Cortrophin Gel from Merck & Co. in 2016. The Company has made a significant investment over the past five years in establishing and updating manufacturing processes and ensuring a sustainable, U.S.-based supply chain. ANI submitted an sNDA to the FDA in June 2021 to bring Cortrophin Gel back to market for patients, physicians and an overall healthcare system in need of greater access to ACTH therapies.

As part of its commitment to ensuring optimal access to Cortrophin Gel, ANI is investing in and will launch a patient support program including financial assistance such as copay cards, for eligible patients. Additional details on the program will be provided in conjunction with the commercial launch.

Tags : #ANIPharmaceuticals #Cortrophingel #FDAClearance #MultipleSclerosis #RheumatoidArthritis #NephroticSyndrome

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

NephroPlus Sets Guinness World Record & India Book of Records Title for Largest Kidney Health Screening DriveMarch 12, 2025
India Choosing to Eat Healthy; Order Volumes Up by 60% for Nutritional ProductsMarch 12, 2025
Amrita students win first prize at DecodeX 2025 hackathonMarch 12, 2025
Why Millions Are Losing Their Sight to Glaucoma And How You Can Prevent ItMarch 12, 2025
Çelebi India Ranks 3rd Worldwide in Ground Handling Performance for Turkish CargoMarch 12, 2025
Advancing Road Safety Through Clear Vision: VARS 4.0 Sets Bold AgendaMarch 12, 2025
The Deadly Cost of the “Perfect Body”: When Diet Trends Turn FatalMarch 12, 2025
Lighthouse Canton’s LC GenInnov Global Innovation Fund Secures Investment from Kotak Mahindra Asset ManagementMarch 11, 2025
TTK Prestige Revolutionizes Cooking with Innovative AirFlip Two-in-One Air Fryer and GrillMarch 11, 2025
Rewriting Immunology: The Discovery That Could Replace Traditional AntibioticsMarch 11, 2025
Is Your Cooking Oil Poisoning You? The Truth About Seed OilsMarch 11, 2025
Think Before You Bite: How Fatty Foods Can Trigger Brain Damage in Just 3 DaysMarch 11, 2025
Ditch the Pills: The Secret to Beating Insomnia is in Your WorkoutMarch 11, 2025
The University of Tasmania invites applications for Master of Public HealthMarch 11, 2025
CBM India Celebrates International Women's Day with Free Eye Screening in HyderabadMarch 11, 2025
Is patriarchy petrifying governments to deliver on gender equality?March 11, 2025
Bihar Hosts Fifth State-Level Consultation on Glaucoma PreventionMarch 10, 2025
Global College of Pharmaceutical Technology Hosts GIPCON 2025: A Convergence of Innovation & ExpertiseMarch 10, 2025
TIPS FOR PARENTS TO COMBAT INCREASING OBESITY AMONG CHILDRENMarch 10, 2025
Medanta hosts the second edition of its annual women’s conclave – Medanta Shakti’25, Celebrating women’s achievements and raising awareness on late pregnancies March 10, 2025